| Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor | journal | October 1993 | 
    | Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity | journal | March 2012 | 
    | Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: Implications for TNF receptor activation | journal | May 1993 | 
    | Exploring “one-shot” kinetics and small molecule analysis using the ProteOn XPR36 array biosensor | journal | November 2006 | 
    | Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity | journal | August 2014 | 
    | Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape | journal | August 2017 | 
    | The Crystal Structure of the Costimulatory OX40-OX40L Complex | journal | August 2006 | 
    | Mechanistic Basis for Functional Promiscuity in the TNF and TNF Receptor Superfamilies: Structure of the LIGHT:DcR3 Assembly | journal | September 2014 | 
    | Crystal Structure of the Complex of Human FasL and Its Decoy Receptor DcR3 | journal | November 2016 | 
    | A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity | journal | December 2009 | 
    | The molecular architecture of the TNF superfamily | journal | January 2002 | 
    | Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors | journal | June 1997 | 
    | The promise and challenges of immune agonist antibody development in cancer | journal | June 2018 | 
    | Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion | journal | September 2020 | 
    | Dimerization of LT R by LT 1 2 is necessary and sufficient for signal transduction | journal | November 2013 | 
    | cDNA sequences of two inducible T-cell genes. | journal | March 1989 | 
    | Evidence for a Role of a Tumor Necrosis Factor-α (TNF-α)-converting Enzyme-like Protease in Shedding of TRANCE, a TNF Family Member Involved in Osteoclastogenesis and Dendritic Cell Survival | journal | May 1999 | 
    | CD28-independent, TRAF2-dependent Costimulation of Resting T Cells by 4-1BB Ligand | journal | June 1998 | 
    | Galectin-9 controls the therapeutic activity of 4-1BB–targeting antibodies | journal | June 2014 | 
    | CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition | journal | January 2016 | 
    | Phaser crystallographic software | journal | July 2007 | 
    | Solution of the structure of the TNF-TNFR2 complex | journal | August 2011 | 
    | MolProbity : all-atom structure validation for macromolecular crystallography | journal | December 2009 | 
    | XDS | journal | January 2010 | 
    | Features and development of Coot | journal | March 2010 | 
    | Immune regulation by 4-1BB and 4-1BBL: complexities and challenges | journal | May 2009 | 
    | Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma: Development of ipilimumab for advanced melanoma | journal | June 2013 | 
    | Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors | journal | June 2017 | 
    | Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy | journal | August 2017 | 
    | Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion | journal | October 2009 | 
    | Influence of immunoglobulin isotype on therapeutic antibody function | journal | March 2016 | 
    | Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production | journal | April 2011 | 
    | Routes of Delivery for CpG and Anti-CD137 for the Treatment of Orthotopic Kidney Tumors in Mice | journal | May 2014 | 
    | Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model | journal | July 2014 | 
    | 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity | journal | June 2015 | 
    | Soluble CD137 (4-1BB) Ligand Is Released Following Leukocyte Activation and Is Found in Sera of Patients with Hematological Malignancies | journal | October 2001 | 
    | ERK-Dependent Bim Modulation Downstream of the 4-1BB-TRAF1 Signaling Axis Is a Critical Mediator of CD8 T Cell Survival In Vivo | journal | June 2008 | 
    | Improving biosensor analysis | journal | September 1999 | 
    | Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor | journal | October 1993 | 
    | Regulation of 4-1BB expression by cell-cell interactions and the cytokines, interleukin-2 and interleukin-4 | journal | February 1995 | 
    | UCSF Chimera?A visualization system for exploratory research and analysis | journal | January 2004 | 
    | Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity | journal | March 2012 | 
    | Exploring the gas access routes in a [NiFeSe] hydrogenase using crystals pressurized with krypton and oxygen | journal | August 2020 | 
    | Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: Implications for TNF receptor activation | journal | May 1993 | 
    | Tumor necrosis factor receptor superfamily members and their ligands | journal | June 1994 | 
    | The Structure of Tumor Necrosis Factor-α at 2.6 Å Resolution | journal | October 1989 | 
    | The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis | journal | December 1999 | 
    | The molecular architecture of the TNF superfamily | journal | January 2002 | 
    | Modularity in the TNF-receptor family | journal | February 1998 | 
    | Exploring “one-shot” kinetics and small molecule analysis using the ProteOn XPR36 array biosensor | journal | November 2006 | 
    | Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies | journal | April 2018 | 
    | Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity | journal | August 2014 | 
    | Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape | journal | August 2017 | 
    | Inference of Macromolecular Assemblies from Crystalline State | journal | September 2007 | 
    | Assessing and maximizing data quality in macromolecular crystallography | journal | October 2015 | 
    | The Crystal Structure of the Costimulatory OX40-OX40L Complex | journal | August 2006 | 
    | Mechanistic Basis for Functional Promiscuity in the TNF and TNF Receptor Superfamilies: Structure of the LIGHT:DcR3 Assembly | journal | September 2014 | 
    | Crystal Structure of the Complex of Human FasL and Its Decoy Receptor DcR3 | journal | November 2016 | 
    | A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity | journal | December 2009 | 
    | A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells | journal | February 1997 | 
    | The immune synapse clears and excludes molecules above a size threshold | journal | November 2014 | 
    | Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors | journal | June 1997 | 
    | Evolving synergistic combinations of targeted immunotherapies to combat cancer | journal | July 2015 | 
    | Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations | journal | March 2016 | 
    | The promise and challenges of immune agonist antibody development in cancer | journal | June 2018 | 
    | PARP1 exhibits enhanced association and catalytic efficiency with γH2A.X-nucleosome | journal | December 2019 | 
    | Assembly and structural properties of glucocorticoid-induced TNF receptor ligand: Implications for function | journal | November 2007 | 
    | Dimerization of LT R by LT 1 2 is necessary and sufficient for signal transduction | journal | November 2013 | 
    | cDNA sequences of two inducible T-cell genes. | journal | March 1989 | 
    | Evidence for a Role of a Tumor Necrosis Factor-α (TNF-α)-converting Enzyme-like Protease in Shedding of TRANCE, a TNF Family Member Involved in Osteoclastogenesis and Dendritic Cell Survival | journal | May 1999 | 
    | The Structure of the Trimer of Human 4-1BB Ligand Is Unique among Members of the Tumor Necrosis Factor Superfamily | journal | December 2009 | 
    | Crystallographic and Mutational Analysis of the CD40-CD154 Complex and Its Implications for Receptor Activation | journal | February 2011 | 
    | CD28-independent, TRAF2-dependent Costimulation of Resting T Cells by 4-1BB Ligand | journal | June 1998 | 
    | Galectin-9 controls the therapeutic activity of 4-1BB–targeting antibodies | journal | June 2014 | 
    | CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition | journal | January 2016 | 
    | Phaser crystallographic software | journal | July 2007 | 
    | MolProbity : all-atom structure validation for macromolecular crystallography | journal | December 2009 | 
    | XDS | journal | January 2010 | 
    | Features and development of Coot | journal | March 2010 | 
    | Solution of the structure of the TNF-TNFR2 complex | journal | August 2011 | 
    | Immune regulation by 4-1BB and 4-1BBL: complexities and challenges | journal | May 2009 | 
    | Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma: Development of ipilimumab for advanced melanoma | journal | June 2013 | 
    | Solution of the Structure of the TNF-TNFR2 Complex | journal | November 2010 | 
    | Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody | journal | October 2016 | 
    | Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors | journal | June 2017 | 
    | Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy | journal | August 2017 | 
    | Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses | journal | April 2009 | 
    | Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion | journal | October 2009 | 
    | Influence of immunoglobulin isotype on therapeutic antibody function | journal | March 2016 | 
    | Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies | journal | January 2018 | 
    | Pembrolizumab | journal | August 2015 | 
    | A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer. | journal | May 2014 | 
    | A phase I study of PF-05082566 (anti-4-1BB) + rituximab in patients with CD20+ NHL. | journal | May 2015 | 
    | Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production | journal | April 2011 | 
    | Routes of Delivery for CpG and Anti-CD137 for the Treatment of Orthotopic Kidney Tumors in Mice | journal | May 2014 | 
    | Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model | journal | July 2014 | 
    | Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway | journal | January 2015 | 
    | 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity | journal | June 2015 | 
    | Functional Characteristics of the High Affinity IgG Receptor, FcγRI | journal | February 2011 | 
    | Soluble CD137 (4-1BB) Ligand Is Released Following Leukocyte Activation and Is Found in Sera of Patients with Hematological Malignancies | journal | October 2001 | 
    | ERK-Dependent Bim Modulation Downstream of the 4-1BB-TRAF1 Signaling Axis Is a Critical Mediator of CD8 T Cell Survival In Vivo | journal | June 2008 |